Clinical Trial News and Research

RSS

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

The American Society for Radiation Oncology appreciates yesterday's ruling by the United States Supreme Court affirming the Affordable Care Act in its decision on King v. Burwell.

27 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

Study: High blood pressure linked to lower risk for Alzheimer's disease

A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer's disease.

27 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

University of North Carolina School of Medicine researchers have developed an innovative, experimental gene transfer-based treatment for children with giant axonal neuropathy (GAN).

26 Jun 2015

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.

26 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

For the first time, researchers at Fred Hutchinson Cancer Research Center have found that weight loss, in combination with vitamin D supplementation, has a greater effect on reducing chronic inflammation than weight loss alone. Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.

26 Jun 2015

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

25 Jun 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

Cognitive behavioural therapy can change brain function of people with Tourette syndrome

In addition to its effect on chronic tics, cognitive behavioural therapy (CBT) can change the brain function of people with Tourette syndrome.

25 Jun 2015

Weight loss along with vitamin D supplementation reduces chronic inflammation

25 Jun 2015

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

25 Jun 2015

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns.

25 Jun 2015

WHO prequalifies new male circumcision device to prevent HIV

The ShangRing, a novel medical device for voluntary medical male circumcision, has received prequalification from the World Health Organization (WHO) for use.

25 Jun 2015

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2020 - forecasts the breast cancer treatment market to increase in value from $9.2 billion in 2013 to more than $13.1 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.1%.

24 Jun 2015

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold.

24 Jun 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015

CardiAQ Valve Technologies announces first human implant of transcatheter bioprosthetic mitral heart valve

CardiAQ Valve Technologies (CardiAQ), which has developed the world’s first self-conforming and self-anchoring technology for nonsurgical transfemoral-transseptal percutaneous Transcatheter Mitral Valve Implantation (TMVI), today announced that its second-generation bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment into a 72-year-old male suffering from severe mitral regurgitation (MR 4+) with multiple co-morbidities and ineligible for alternate treatment modalities.

24 Jun 2015

'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of the device that restores vision in those blinded by a rare, degenerative eye disease.

24 Jun 2015

Clinical Trial News and Research

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Study: High blood pressure linked to lower risk for Alzheimer's disease

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Cognitive behavioural therapy can change brain function of people with Tourette syndrome

Weight loss along with vitamin D supplementation reduces chronic inflammation

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

WHO prequalifies new male circumcision device to prevent HIV

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

TxCell’s pilot manufacturing facility activities put on temporary partial hold

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

CardiAQ Valve Technologies announces first human implant of transcatheter bioprosthetic mitral heart valve

'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer